WO2006113796A3 - Microbial cellulose materials for use in transdermal drug delivery system - Google Patents

Microbial cellulose materials for use in transdermal drug delivery system Download PDF

Info

Publication number
WO2006113796A3
WO2006113796A3 PCT/US2006/014724 US2006014724W WO2006113796A3 WO 2006113796 A3 WO2006113796 A3 WO 2006113796A3 US 2006014724 W US2006014724 W US 2006014724W WO 2006113796 A3 WO2006113796 A3 WO 2006113796A3
Authority
WO
WIPO (PCT)
Prior art keywords
microbial cellulose
delivery system
drug delivery
transdermal drug
cellulose materials
Prior art date
Application number
PCT/US2006/014724
Other languages
French (fr)
Other versions
WO2006113796A2 (en
Inventor
Gonzalo Serafica
Christopher Damien
Gerry Ann Oster
Kevin Lentz
Russell Hoon
Original Assignee
Xylos Corp
Gonzalo Serafica
Christopher Damien
Gerry Ann Oster
Kevin Lentz
Russell Hoon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xylos Corp, Gonzalo Serafica, Christopher Damien, Gerry Ann Oster, Kevin Lentz, Russell Hoon filed Critical Xylos Corp
Priority to JP2008507835A priority Critical patent/JP2008536937A/en
Publication of WO2006113796A2 publication Critical patent/WO2006113796A2/en
Publication of WO2006113796A3 publication Critical patent/WO2006113796A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method for transdermally delivering a biologically active agent to a subject in need thereof, comprising topically applying a composition comprising insoluble microbial cellulose, water, and a therapeutically effective amount of the biologically active agent, wherein the biologically active agent penetrates through the subject's stratum corneum at a substantially constant rate.
PCT/US2006/014724 2005-04-20 2006-04-19 Microbial cellulose materials for use in transdermal drug delivery system WO2006113796A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008507835A JP2008536937A (en) 2005-04-20 2006-04-19 Microbial cellulose materials for use in transdermal drug delivery systems, manufacturing and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67288005P 2005-04-20 2005-04-20
US60/672,880 2005-04-20

Publications (2)

Publication Number Publication Date
WO2006113796A2 WO2006113796A2 (en) 2006-10-26
WO2006113796A3 true WO2006113796A3 (en) 2006-12-14

Family

ID=37115908

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/014724 WO2006113796A2 (en) 2005-04-20 2006-04-19 Microbial cellulose materials for use in transdermal drug delivery system

Country Status (2)

Country Link
JP (1) JP2008536937A (en)
WO (1) WO2006113796A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100134078A (en) * 2008-04-16 2010-12-22 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 Method of producing thrombin-immobilized bioabsorbable sheet preparation
US7832857B2 (en) 2008-08-18 2010-11-16 Levinson Dennis J Microbial cellulose contact lens
RU2497679C2 (en) 2008-10-02 2013-11-10 Милан Инк. Method of making multilayer adhesive laminated material
JP5669050B2 (en) * 2010-01-15 2015-02-12 国立大学法人島根大学 Bone cement

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558861A (en) * 1986-04-22 1996-09-24 Ajinomoto Co., Inc. Modified microbially-produced cellulose gel with human epidermal cells adsorbed thereon for use as a skin graft or vulnerary cover
US20040224023A1 (en) * 1996-05-24 2004-11-11 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588400A (en) * 1982-12-16 1986-05-13 Johnson & Johnson Products, Inc. Liquid loaded pad for medical applications
US4655758A (en) * 1982-12-16 1987-04-07 Johnson & Johnson Products, Inc. Microbial polysaccharide articles and methods of production
US5863560A (en) * 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558861A (en) * 1986-04-22 1996-09-24 Ajinomoto Co., Inc. Modified microbially-produced cellulose gel with human epidermal cells adsorbed thereon for use as a skin graft or vulnerary cover
US20040224023A1 (en) * 1996-05-24 2004-11-11 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways

Also Published As

Publication number Publication date
WO2006113796A2 (en) 2006-10-26
JP2008536937A (en) 2008-09-11

Similar Documents

Publication Publication Date Title
del Consuelo et al. Ex vivo evaluation of bioadhesive films for buccal delivery of fentanyl
TW200502017A (en) Active agent delivery device having composite members
WO2005112984A3 (en) Apparatus and method for transdermal delivery of parathyroid hormone agents
NZ546992A (en) Transdermal drug delivery device
DK0957900T3 (en) Compositions and Methods for Topical Application of Therapeutic Agents
EP2155175B1 (en) Matrix-type transdermal drug delivery system and preparation method thereof
JP2006525316A5 (en)
TW200517156A (en) Pretreatment method and system for enhancing transdermal drug delivery
EP2001453A4 (en) Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
EP2266533A3 (en) Transdermal delivery rate control using amorphous pharmaceutical compositions
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
WO2001052823A3 (en) Compositions to effect the release profile in the transdermal administration of drugs
EP0857488A1 (en) Methods and compositions for enhancing skin permeation of drugs using permeation enhancers
TW200815045A (en) Pharmaceutical compositions of ropinirole and methods of use thereof
MXPA03003815A (en) Transdermal drug delivery devices having coated microprotrusions.
WO2005102334A3 (en) Apparatus and method for transdermal delivery of fentany-based agents
TW200618830A (en) Micorprojection apparatus and system with low infection potential
WO2004030743A3 (en) Drug delivery device having coated microprojections incorporating vasoconstrictors
WO2010034019A4 (en) Transdermal drug delivery using an osmolyte and vasoactive agent
WO2011029948A3 (en) Transdermal therapeutic system for administering fentanyl or an analogue thereof
TW200514590A (en) Hydrophilic adhesives for delivery of herbal medicines
AU2003215657A1 (en) Hormone-containing transdermal therapeutic system with an active substance reservoir based on vinylacetate-vinylpyrrolidone copolymer with improved cohesion.
WO2005067499A3 (en) Method and device for topical delivery of therapeutic agents to the skin
JP2006525315A5 (en)
WO2006113796A3 (en) Microbial cellulose materials for use in transdermal drug delivery system

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2008507835

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) (THE EPO COMMUNICATION FORM 1205A HAS BEEN SENT ON27/03/2008)

122 Ep: pct application non-entry in european phase

Ref document number: 06750699

Country of ref document: EP

Kind code of ref document: A2